BET inhibitors as novel therapeutic agents in breast cancer

Alberto Ocaña; Cristina Nieto-Jiménez; Atanasio Pandiella

doi:10.18632/oncotarget.19744

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

BET inhibitors as novel therapeutic agents in breast cancer

Alberto Ocaña _, Cristina Nieto-Jiménez and Atanasio Pandiella

PDF | HTML | How to cite

Oncotarget. 2017; 8:71285-71291. https://doi.org/10.18632/oncotarget.19744

Metrics: PDF 2417 views | HTML 3373 views | ?

Abstract

Alberto Ocaña1, Cristina Nieto-Jiménez1 and Atanasio Pandiella2

1Unidad de Investigación Traslacional, Hospital Universitario de Albacete, Universidad de Castilla La Mancha, Albacete, Spain

2Instituto de Biología Molecular y Celular del Cáncer and CIBERONC, CSIC-Universidad de Salamanca, Salamanca, Spain

Correspondence to:

Alberto Ocaña, email: [email protected]

Keywords: breast cancer, BET inhibitors, novel targets

Received: May 16, 2017 Accepted: June 28, 2017 Published: August 01, 2017

ABSTRACT

Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting proteins of the transcription machinery, recognizing acetylated-lysine residues in nucleosomal histones. Bromodomain and extra-terminal (BET) inhibitors have shown to produce growth inhibition in several tumors through the inhibition of the expression of several transcription factors. In this review we will discuss the current knowledge regarding BET inhibitors in breast cancer. Recent data demonstrates their antiproliferative effect in several cancer subtypes, including the triple negative subtype, or when combined with cell signaling inhibitors. We will also describe options for therapeutic combinations or potential mechanisms of resistance, with special emphasis on their future clinical development.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19744

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

BET inhibitors as novel therapeutic agents in breast cancer

Abstract